Introduction: Invasive fungal infection (IFI) incur signifi cant morbidity and mortality among children undergone Allogeneic Stem Cell Transplantation (Allo-SCT) due to neutropenic phase and posterior immunosuppression. We have analyzed in this prospective study our experience in pediatric patients who received voriconazole as primary antifungal prophylaxis undergone Allo-SCT. Methods and patients: A total of 50 children and adolescents 2.5 basal levels in 7 (14%) children. Skin rash (n = 1), pancreatitis (n = 1) and tremor (n = 1) were the others secondary effects observed. All adverse effects were solved once stopped voriconazole. Conclusion: With an overall IFI incidence of 2%, our results suggest that primary antifungal prophylaxis in children undergone Allo-SCT with voriconazole is effective at reducing the incidence of IFI in this type of high risk pediatric patients. Voriconazole is well tolerated despite a high percentage of adverse effects easily solved by drug stopped without life-threatening complications.
Full conference title:
Annual Meeting of the EBMT, 36th
- EBMT 36th (2010)